Parkodin (Acetaminophen,Codeine)

Quick links to important sections

Parkodin (Acetaminophen,Codeine)

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parkodin (Acetaminophen,Codeine)

Property Description
Active ingredient Acetaminophen, Codeine
Form Oral tablets
Pharmacological class Combination Analgesic (Opioid and Non-Opioid)
Common use Management of pain (mild to moderately severe)
Origin Synthetic (Acetaminophen) and Semi-synthetic (Codeine)

Parkodin is defined as a specific fixed-dose combination product containing the active ingredients Acetaminophen (Paracetamol) and Codeine, providing a dual-mechanism approach to analgesia. This formulation is clinically recognized for its ability to deliver comprehensive pain management for patients experiencing mild to moderately severe pain when single-agent non-opioids are inadequate. The preparation is typically manufactured in the dosage form of oral tablets, making its route of administration oral.

The medication's fundamental composition relies on the synthetic non-opioid analgesic Acetaminophen and the semi-synthetic opiate derivative Codeine. This combination is formally classified as an analgesic due to the necessity of combining a peripherally acting agent with a centrally acting agent. This structure establishes the drug as a powerful Combination Analgesic. Popular brands sharing this essential formulation include Tylenol with Codeine and Co-codamol, further distinguishing it as a widely supported solution for enhanced pain relief.

The design as a fixed-dose combination product is a strategic polypharmacy approach that ensures the synergistic effect of the two active substances is achieved reliably in every tablet. This design is crucial because the components rely on separate mechanisms of effect—the peripheral action of Acetaminophen complements the central pain-perception influence of Codeine. The resultant benefit is a capacity to address pain signals more broadly, often being utilized in neutral use scenarios such as post-dental procedure discomfort or pain following minor injuries.

Regulatory References

  1. Acetaminophen and Codeine combination product - MedlinePlus

What side effects are possible with Parkodin (Acetaminophen,Codeine)?

Possible side effects and safety information

The safety profile for this fixed-dose combination product of Acetaminophen and Codeine is defined by authoritative regulatory classifications of adverse reactions, organized by frequency and the body system affected.

Key Adverse Reaction Scope

Adverse effects are commonly categorized based on the affected System-Organ Class. Nervous System Disorders frequently involve drowsiness, sedation, and dizziness. Gastrointestinal Disorders typically include nausea, vomiting, and constipation, which are classified as common effects in official regulatory documents. Other documented effects may include rash and pruritus.

Serious Adverse Reactions and Key Constraints

The official labeling highlights risks related to each active substance. The primary risk associated with the Acetaminophen component is hepatotoxicity, which can lead to acute liver failure. The Codeine component carries a risk of life-threatening respiratory depression and the potential for addiction, abuse, and misuse. The risk of respiratory depression is officially noted to be greatest upon the initiation of therapy or following a dose increase.

Regulatory authorities mandate specific safety constraints for vulnerable populations. The product is contraindicated in children under 12 years of age and in individuals known to be CYP2D6 ultra-rapid metabolizers. Use is also restricted in nursing mothers due to the potential for the metabolite to pass into breast milk. Caution is generally advised for older adults and patients with hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Regulatory documents define the overdose profile of this combination product based on the distinct, severe toxicities of its two components: acetaminophen and codeine.

Toxicity Component Documented Overdose Manifestations
Acetaminophen Nausea, vomiting, anorexia, and diaphoresis in the initial phase. Delayed signs include liver damage, elevated hepatic enzymes, and acute liver failure, which may result in death.
Codeine Profound sedation, stupor, somnolence, and life-threatening respiratory depression. Other signs include pinpoint pupils (miosis), hypotension, and circulatory collapse.

Severe Outcomes and Emergency Actions

Overdose may result in fatal hepatic necrosis (liver failure) from the acetaminophen component and fatal respiratory depression from the codeine component. Immediate medical attention must be sought upon ingestion of an excessive amount, even if the patient feels well, due to the potential for delayed, severe liver damage. If signs of severe opioid overdose are present, medical attention should be sought immediately.

Management procedures, as described in official labeling, include providing symptomatic and supportive treatment, maintaining an open airway, and utilizing specific antidotes. N-acetylcysteine is the specific antidote for acetaminophen toxicity, and Naloxone is used to reverse the effects of the codeine component.

Therapeutic Uses of Parkodin (Acetaminophen,Codeine)

This medication is commonly used across conditions presenting with symptoms related to physical discomfort that are classified as mild to moderately severe. It is generally applied when symptoms become more disruptive during flare-ups and when initial management with non-opioid options is considered inadequate.

This combination is relevant in clinical settings that involve acute or unstable symptom patterns, such as managing pain following minor injuries, dental procedures, or outpatient surgeries. It may assist with managing symptom clusters that create noticeable functional strain. The product is applied across therapeutic domains where additional symptomatic support is needed, addressing groups of symptoms that appear suddenly, including both discomfort and the systemic imbalance of fever.

“The medication is relevant for easing challenging symptoms, and it supports patients during episodes of heightened discomfort by helping to manage both manifestations.”

This contributes to easing the overall symptom load, which supports general well-being during symptomatic phases.


Quick Fact: Relief for Mild to Moderately Severe Pain This combination analgesic is considered relevant for easing challenging symptoms when pain is not adequately controlled by single-agent medications alone, supporting patients during difficult episodes.

Eligibility and Restrictions for Use

The eligibility rules for using Parkodin (Acetaminophen, Codeine) are strictly defined by regulatory authorities. The medicine is contraindicated and must not be used in several populations. This includes all children younger than 12 years of age, and adolescents under 18 who have recently undergone tonsillectomy or adenoidectomy. Use is also prohibited for breastfeeding mothers and individuals known to be CYP2D6 ultra-rapid metabolizers of codeine. Patients with severe bronchial asthma, significant respiratory depression, or known hypersensitivity to either acetaminophen or codeine should not use this medication.

Other groups require caution and monitoring. Older adults and patients with hepatic impairment (liver disease) or renal impairment (kidney disease) must use the medicine under restricted conditions, often requiring a dose adjustment. Adolescents aged 12 to 18 with specific risk factors like severe lung disease or obesity should avoid use. Pregnant women are advised to avoid prolonged use due to the risk of Neonatal Opioid Withdrawal Syndrome. Use also requires caution in patients with conditions such as increased intracranial pressure or seizure disorders.

What should I know about interactions with other medicines?

The codeine component of this product, an opioid pro-drug, is subject to significant drug interactions primarily through its metabolism by liver enzymes, most notably Cytochrome P450 (CYP) 2D6 and CYP3A4. Concomitant use with certain medicines or substances can alter the concentration of the active metabolite, morphine, leading to potential risks.

Major Interaction Categories

Interacting Product Category Mechanism and Risk Classification
CNS Depressants & Alcohol Additive depressant effects, risking profound sedation, severe respiratory depression, coma, and death. This is classified as a major interaction.
CYP2D6 Inhibitors Reduce the conversion of codeine to active morphine. This may lead to decreased analgesic efficacy or signs of opioid withdrawal.
CYP3A4 Inhibitors Can increase codeine plasma concentration, potentially enhancing metabolism to morphine via CYP2D6, raising the risk of opioid toxicity and respiratory depression.
MAOIs (Monoamine Oxidase Inhibitors) Concurrent use is contraindicated due to the risk of severe, potentially fatal interactions, including serotonin syndrome. A minimum 14-day washout period is required.
Serotonergic Drugs Increased risk of developing serotonin syndrome.
Coumarin Anticoagulants Acetaminophen may increase the effect of anticoagulants like warfarin, requiring close monitoring of the International Normalized Ratio (INR).

Clinical and Pharmacogenetic Constraints

The product is contraindicated in patients known to be CYP2D6 ultra-rapid metabolizers due to the danger of life-threatening respiratory depression from excessive morphine conversion. Due to CNS depression risks, co-prescribing with benzodiazepines or other CNS depressants must be reserved only for when alternative options are inadequate, and the dosage and duration should be limited to the minimum required. Consumption of grapefruit and grapefruit juice should be avoided due to its potential to inhibit CYP3A4.

Mechanism of Action

How Parkodin (Acetaminophen,Codeine) Works

Parkodin engages a dual mechanistic strategy to modulate nociceptive (pain signal) transmission across relevant central neural and biochemical pathways. The combination establishes a dual pattern of interference affecting both perception and mediator synthesis.

Central Opioid Receptor Engagement

Codeine functions as a prodrug, undergoing metabolism to its active form, Morphine. Morphine acts as an agonist by binding to mu (mu) opioid receptors primarily within the central nervous system (CNS). This interaction modulates the release of neurotransmitters, resulting in diminished nociceptive signal transmission and subsequent central processing of afferent pain signals.

Central Prostaglandin Pathway Interference

The action of Acetaminophen involves the inhibition of prostaglandin synthesis, which are lipid mediators of pain and fever. This occurs predominantly in the CNS through modulation of the Cyclooxygenase (COX) enzyme system. This mechanism reduces the activity within central pathways that facilitate nociception and adjusts hypothalamic thermoregulatory set-points.

Dual Pathway Interference

This combined mechanistic engagement simultaneously targets both the central neural pathways (Morphine agonism) and the biochemical mediator synthesis (Acetaminophen inhibition). The dual pathway engagement alters the signaling patterns across multiple central pathways, influencing the integrated response to nociception.

Dosage and Administration Information

How to Use Parkodin (Acetaminophen, Codeine): Administration Guidelines

This combination analgesic is designated exclusively for oral administration, primarily available in tablet form or as an oral solution. Guidelines establish precise parameters for how this medication is used, focusing on dosage, frequency, and duration.


Standard Dosing and Frequency

The typical adult regimen involves taking one to two tablets (containing the approved fixed-dose strengths) per dose. The frequency is determined by the minimum interval between administrations, which is generally every 4 to 6 hours as needed for discomfort. The maximum daily intake is a critical constraint: the total dose of Acetaminophen (Paracetamol) must not exceed 4,000 mg (4 g) in a 24-hour period. Dosing instructions uniformly emphasize using the lowest effective dosage for the shortest duration necessary.


Administration Context and Special Populations

The tablets may be taken with or without food. A key procedural constraint is the Co-Administration Restriction, which mandates that patients must not concurrently take any other products containing acetaminophen or paracetamol to prevent exceeding the maximum daily dose.

Administration rules specify adjustments for vulnerable groups:

  • Pediatric Use: The medication is contraindicated in all children younger than 12 years of age.
  • Impaired Organ Function: The time between doses must be extended for patients with moderate to severe renal or hepatic impairment to allow for proper drug clearance.

Duration and Discontinuation

Treatment is fundamentally defined as short-term use for acute symptomatic episodes. Where physical dependence has occurred, the dosage is gradually reduced (tapered) when discontinuing the product to mitigate withdrawal effects.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Chronic Pain Management

Studies have investigated the role of the combination compound in assessing changes in pain severity across various conditions. Research has primarily focused on the potential benefit of combining a non-opioid analgesic (acetaminophen) with an opioid analgesic (codeine) to target multiple pain pathways.

  • Low Back Pain: Trials reviewed whether the compound was studied for potential changes in reported pain and measured function in patients with chronic low back pain. One study comparing the combination to another analgesic found comparable efficacy but a higher incidence of adverse events with the acetaminophen/codeine group.
  • Osteoarthritis: Several studies have investigated the compound's effect on pain and joint mobility in patients with knee and hip osteoarthritis, with outcomes measured by scales such as the WOMAC index.

Acute Pain Conditions

Meta-analyses have assessed the magnitude of difference between the compound and placebo in managing acute pain, such as postoperative or dental pain. For acute postsurgical pain, the combination was associated with better relief than placebo or acetaminophen alone, but studies comparing it directly to nonsteroidal anti-inflammatory drugs (NSAIDs) often show similar or sometimes reduced pain scores and more adverse effects for the codeine combination.

Safety and Tolerability Profile

Long-term studies have primarily focused on the tolerability of the compound. This research investigated whether the compound demonstrated acceptable tolerability for continuous use. The overall incidence of adverse events in the active group was often comparable to control groups, but side effects related to the opioid component, such as constipation, nausea, and somnolence, were more frequently observed. Due to the codeine component, the compound carries a risk of dependence and misuse, which is often addressed through risk evaluation and mitigation strategies (REMS) programs.

Frequently Asked Questions (FAQ)

Common questions about Parkodin (Acetaminophen,Codeine) (FAQ)


Q: How is the pain relief from Parkodin different from plain Acetaminophen (Paracetamol)?

The official classification of Parkodin indicates it is a combination product for the management of mild to moderately severe pain when a non-opioid medicine alone is not considered adequate. The difference lies in the addition of the Codeine component, which acts centrally on the brain’s opioid receptors. This dual mechanism is intended to address pain signals more broadly than Acetaminophen alone.


Q: How long does it usually take to feel the pain relief effect after taking Parkodin?

According to official prescribing information, the analgesic effect typically begins to be felt within the first hour of administration. The pain relief is officially documented to reach its peak effect within two hours following administration.


Q: What is the typical duration of action for a single dose of Parkodin?

The official product information indicates that the pain-relieving effect of a single dose generally persists between four and six hours. This duration aligns with the typical interval between doses described in regulatory documents.


Q: Is it normal to feel drowsy or sleepy when first starting Parkodin?

Official regulatory documents list drowsiness and sedation as common adverse effects associated with this medicine. These effects are often noted to occur, particularly when therapy is first initiated or if a dose has been increased.


Q: What is the difference between physical dependence and addiction for this medicine?

Official labeling distinguishes between these two concepts. Physical dependence is described as a physiological state where the body adapts to the drug's presence after regular use, causing specific withdrawal symptoms if the medicine is suddenly stopped. Addiction is defined separately as a behavioral pattern characterized by compulsive use of the medicine despite harm.


Q: Can women who are breastfeeding use Parkodin?

Use of this medicine is generally not recommended or is contraindicated (prohibited) for women who are breastfeeding. This is because the codeine component can pass into breast milk and may potentially cause serious adverse effects for the infant.


Q: Is there a known genetic factor that affects how some people respond to the codeine part of Parkodin?

Yes, official safety information highlights that a specific gene for the CYP2D6 enzyme affects how codeine is processed into its active form, morphine. Differences in this gene's activity can lead to varied responses to the medicine.


Q: Can taking Parkodin interact with herbal supplements or vitamins?

Regulatory guidance notes the possibility of interactions with some herbal products and certain vitamins. For example, some official information notes that certain herbal products have been associated with potential interactions, which could affect drug levels in the body.


Q: Is it safe to drive or operate machinery after taking Parkodin?

Official guidance warns that the medicine may impair the mental or physical abilities required for operating potentially hazardous equipment. Individuals should avoid operating machinery or driving until they understand how the medication affects their specific abilities.


Q: What are the general risks of using Parkodin during pregnancy?

If this medicine is used regularly for a long period during pregnancy, the baby may be at risk of developing Neonatal Opioid Withdrawal Syndrome (NOWS) after birth. The potential risks of use during pregnancy are described in official documents, and discussion with a healthcare provider is recommended regarding the specific situation.


Q: Why are people sometimes referred to as 'ultra-rapid metabolizers' of codeine?

This designation is used for people whose bodies process codeine into morphine more rapidly and completely than normal. This increased rate of metabolism is linked to a specific genetic variation in the CYP2D6 enzyme, which raises the risk of severe respiratory depression.


Q: What happens if the pain does not go away after taking Parkodin as prescribed?

Official patient guidance emphasizes that patients are directed to report to their healthcare professional if their pain persists, worsens, or changes in nature. The guidance emphasizes that patients should not increase the prescribed dose or change the administration schedule without professional consultation.


Q: What is Serotonin Syndrome and is it associated with Parkodin?

Serotonin syndrome is a serious, potentially life-threatening condition caused by an excessive level of the chemical serotonin in the central nervous system. Regulatory information notes that this syndrome is a risk when opioids, like codeine, are combined with other medicines that affect the body's serotonin levels (serotonergic drugs).


Q: Can Parkodin affect a person's mood or cause emotional changes?

Official product information mentions that the opioid component, codeine, may cause changes in mood. These changes can include feelings of euphoria (intense well-being) or dysphoria (unease or dissatisfaction).


Q: Are there known symptoms of withdrawal if Parkodin is stopped suddenly after regular use?

Yes, if the medicine is stopped abruptly after long-term regular use, patients may experience withdrawal symptoms. These symptoms, described in official documents, can include restlessness, yawning, watery eyes, runny nose, sweating, muscle aches, anxiety, and difficulty sleeping.


Q: Can Parkodin cause problems with sleeping, like insomnia or difficulty staying awake?

While the medicine is commonly associated with effects like drowsiness and somnolence (sleepiness), official product safety information also lists potential side effects like insomnia (difficulty falling or staying asleep) and nervousness.


Q: Does Parkodin affect blood pressure?

Official documents indicate that the opioid component can cause hypotension (low blood pressure). This can include orthostatic hypotension, which is a drop in blood pressure that causes dizziness or lightheadedness when a person stands up too quickly.


Q: What are the risks of taking Parkodin if a person has a history of breathing issues like asthma or sleep apnea?

Official warnings advise that the medicine should be used with caution in patients who have a history of conditions like asthma, COPD, or sleep apnea. The opioid component may worsen existing respiratory depression (slowed or troubled breathing).


Q: Can Parkodin cause dry mouth?

Yes, official documents from regulatory authorities list dry mouth (xerostomia) as a potential adverse effect associated with the use of the medicine.


Q: Is there a link between long-term Parkodin use and effects on fertility or sex hormones?

Official information derived from the opioid component states that chronic use may potentially lead to a decrease in fertility in both men and women. This risk is noted in official documents as a topic for discussion with a healthcare provider.


Q: Does Parkodin help with pain that is caused by inflammation?

The Acetaminophen component works by inhibiting the synthesis of prostaglandins, which are biochemicals involved in both pain and fever. While it helps reduce pain signals, Acetaminophen is generally not classified by regulatory bodies as an anti-inflammatory drug, unlike certain other pain relievers.


Q: What are the risks of accidental ingestion of Parkodin by children?

Official warnings emphasize that accidental ingestion, even of a single dose, may be deadly for a child. This risk is due to the opioid component potentially causing severe, life-threatening respiratory depression.


Q: Is Parkodin used for things other than pain relief, such as cough or diarrhea?

While the specific combination tablet is primarily indicated and approved for pain management, the codeine component on its own is known to possess effects like cough suppression and slowing of the bowels. However, these are not the stated primary, approved uses for the combination product.


Q: Can Parkodin cause dizziness or lightheadedness when changing position, like standing up?

Yes, official documents report that the medicine can cause dizziness or lightheadedness due to its potential to cause orthostatic hypotension. This means a patient may feel dizzy when moving suddenly from a seated or lying position to standing.


Q: Does Parkodin lose its effectiveness over time (tolerance)?

Yes. Official information on opioid analgesics indicates that a physiological phenomenon called tolerance can develop with chronic use. Tolerance is defined as the need for increasing doses to achieve the same level of pain relief over time.

How should Parkodin (Acetaminophen,Codeine) be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of Parkodin (Acetaminophen, Codeine) tablets to maintain product stability and prevent misuse.

Condition Type Requirement
Storage Temperature Controlled room temperature, generally 20 C to 25 C (68 F to 77 F); do not freeze.
Environmental Protection Keep in a closed container, protected from heat, moisture, and direct light.
Child Safety Mandatory: Keep strictly out of the reach and sight of children in a secure place due to the risk of accidental opioid overdose.
Disposal Instructions Utilize a drug take-back program or DEA-authorized collector as the preferred method for unused tablets.
Alternative Disposal If a take-back option is unavailable, mix the unused tablets with an undesirable substance (e.g., coffee grounds) in a sealed container and discard in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Parkodin (Acetaminophen,Codeine) found in:

A-Z Index: